Showing results (71-80 of 93) with videos related to

Sort By:
Pageof 10
Clinical Oncology (Royal College of Radiologists (Great Britain))|December 2, 2025
Geriatric Oncology in Italy. Where we are. A CIPOMO (Italian College of Primary Hospital Medical Oncologists)-Gioger (Italian Group of Geriatric Oncology) SurveyS Barni, A Luciani, P Tralongo, et al.
Breast Cancer Research and Treatment|March 15, 2017
Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trialsM V Dieci, A Frassoldati, D Generali, et al.
Breast Cancer Research and Treatment|December 12, 2018
Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trialO Nanni, D Amadori, A De Censi, et al.
European Journal of Cancer (Oxford, England : 1990)|November 28, 2017
Prognostic impact of interval breast cancer detection in women with pT1a N0M0 breast cancer with HER2-positive status: Results from a multicentre population-based cancer registry studyA Musolino, F Falcini, A Sikokis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 7, 2015
Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind studyF Roila, B Ruggeri, E Ballatori, et al.
European Journal of Cancer (Oxford, England : 1990)|December 31, 2002
Response to first-line chemotherapy and long-term survival in patients with multiple myeloma: results of the MM87 prospective randomised protocolA Riccardi, O Mora, C Tinelli, et al.
ESMO Open|April 15, 2022
Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort studyA Lasagna, F Bergami, D Lilleri, et al.
ESMO Open|August 27, 2022
Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concernA Lasagna, F Bergami, D Lilleri, et al.
ESMO Open|October 11, 2025
Interaction between tumor-infiltrating lymphocytes and BMI in early HER2-positive breast cancer: analysis of the ShortHER trialM V Dieci, G Bisagni, S Bartolini, et al.
ESMO Open|January 4, 2025
Survival analysis of the non-metastatic cohort of the Italian Association for Medical Oncology (AIOM) Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy (GARIBALDI)M Reni, M Milella, F Bergamo, et al.
Pageof 10